CAR-T細胞療法市場規模、シェア、動向、2031年までの世界予測

世界のCAR-T細胞療法市場は、2026年の72億4,000万米ドルから2031年には137億8,000万米ドルに達し、年平均成長率（CAGR）13.7%で成長すると予測されています。市場の成長は、主に世界的ながん罹患率の上昇に牽引されています。CAR-T細胞療法における技術の進歩と、治療法開発への投資および資金の増加が、市場の成長を牽引すると予想されます。しかしながら、CAR-T細胞療法に伴う副作用や高額な治療費は、予測期間中の市場成長を抑制する主な要因の一つとなることが予想されます。

調査対象：

本調査レポートでは、CAR-T細胞療法市場を、製品別（YESCARTA、KYMRIAH、CARVYKTI、ABECMA、TECARTUS、BREYANZI、その他）、標的別（CD19、BCMA、その他）、適応症別（多発性骨髄腫、B細胞リンパ腫、急性リンパ性白血病、その他）、人口統計別（成人、小児）、エンドユーザー別（病院、専門センター、長期ケア施設）、地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）に分類しています。

本レポートは、CAR-T細胞療法市場の成長に影響を与える主要な要因（促進要因、課題、機会、制約など）に関する詳細な情報を網羅しています。主要プレーヤーの詳細な分析を実施し、事業概要、製品ポートフォリオ、主要戦略（製品発売、協業、パートナーシップ、事業拡大、契約など）、そしてCAR-​​T細胞療法市場における最近の動向に関する洞察を提供しています。本レポートは、CAR-T細胞療法市場エコシステムにおける主要プレーヤーと新興スタートアップ企業の競合分析を提供します。

レポート購入の主なメリット：

本レポートは、CAR-T細胞療法市場全体とそのサブセグメントの収益に最も近い概算値を提供することで、市場リーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、より効果的な事業ポジショニングと適切な市場開拓戦略の策定に役立つ洞察を得るのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

本レポートは、以下の点について洞察を提供します。

CAR-T細胞療法市場の成長に影響を与える主要な推進要因（CAR-T細胞療法における技術進歩、造血がんにおける強力な有効性シグナルに伴う適応拡大、治療法開発への投資増加）、制約要因（高コストと保険償還の課題）、機会（造血悪性腫瘍から固形がんおよび新たな疾患領域への拡大、同種異系CAR-TおよびCAR-NKへの重点シフト）、および課題（長期安全性監視と適応要件の変化）の分析。

• 製品開発／イノベーション：CAR-T細胞療法市場における新製品に関する詳細な分析。
• 市場開発：有望な市場に関する包括的な情報 ― 本レポートでは、様々な地域におけるCAR-T細胞療法市場を分析しています。
• 市場の多様化：CAR-T細胞療法市場における新製品、未開拓地域、最近の動向、投資に関する包括的な情報。
• 競合評価：CAR-T細胞療法市場における主要企業（ブリストル・マイヤーズ スクイブ社（米国）、ギリアド・サイエンシズ社（米国）、ノバルティスAG（スイス）、ジョンソン・エンド・ジョンソン（米国）、JW（ケイマン）セラピューティクス社（中国）、イムノアクト社（インド）など）の市場シェア、成長戦略、製品ラインナップを詳細に評価しています。

Report Description

The global CAR T-cell therapy market is projected to reach USD 13.78 billion in 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. Market growth is primarily driven by rising global cancer prevalence. Technological advancements in CAR T-cell therapies and rising investment and funding for therapy development are likely to propel market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are among the major factors expected to restrain market growth during the forecast period.

“The Yescarta product segment accounted for the largest share by product in the CAR T-cell therapy market in 2025.”

Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel), and other products.

The Yescarta segment held the largest market share in 2025. Market growth is driven by high response rates and durable remissions with Yescarta in treating relapsed/refractory cancers, leading to increased therapy adoption.

“The hospitals segment accounted for the largest share by end user segment in the CAR T-cell therapy market in 2025.”

Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long-term care facilities, and specialty centers. In 2025, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period.

Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell therapies as more hospitals embrace them. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborating with pharmaceutical companies and hospitals, the evidence base expands, and regulatory approvals accelerate, which, in turn, stimulate market growth.

“Asia Pacific is projected to grow at the highest CAGR in the CAR T-cell therapy market from 2026 to 2031.”

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline, and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in Asia Pacific. In addition, increased collaborations among hospitals, universities, and industries in China are expected to drive robust market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell therapies, positioning the region as a key player in advancing oncology therapeutic outcomes.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
• By Designation: Directors- 20%, Managers- 10%, and Others – 70%,
• By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

• Bristol-Myers Squibb Company (US)
• Gilead Sciences Inc. (US)
• Novartis AG (Switzerland)
• Johnson & Johnson (US)
• CARsgen Therapeutics Holdings Limited (China)
• IASO Biotherapeutics (China)
• JW (Cayman) Therapeutics Co., Ltd (China)
• ImmunoAct (India)
• CRISPR Therapeutics (Switzerland)
• Autolus Therapeutics (UK)
• Allogene Therapeutics (US)
• Cartesian Therapeutics Inc. (US)
• Guangzhou Bio-gene Technology Co., Ltd (China)
• Wugen (US)

Research Coverage:

This research report categorizes the CAR T-cell therapy market by product (YESCARTA, KYMRIAH, CARVYKTI, ABECMA, TECARTUS, BREYANZI, Other products); by target: CD19, BCMA, other targets; by indication: Multiple myeloma, B-cell lymphoma, Acute lymphoblastic leukemia, Other indications; by demographics: adult, pediatric; by End User:  Hospitals, Specialty centers, Long-term care facilities, and by region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the CAR T-cell therapy market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies, such as product launches, collaborations, partnerships, expansions, agreements, and recent developments in the CAR T-cell therapy market. This report provides a competitive analysis of top players and emerging startups in the CAR T-cell therapy market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Technological advancements in CAR T-cell therapies, Label expansions along with strong efficacy signals in hematologic cancers, Growing investments in the development of therapies), restraints (High cost and reimbursement challenges), opportunities (Expanding beyond hematologic malignancies into solid tumors and new disease areas, Focus shift on allogeneic CAR-T and CAR-NK), and challenges (Long-term safety surveillance and evolving labeling requirements) are influencing the growth of CAR T-cell therapy market.

• Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the CAR T-cell therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

Table of Contents

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 32
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32
1.3.2 INCLUSIONS & EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 34
1.5 SUMMARY OF CHANGES 35
2 EXECUTIVE SUMMARY 36
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 36
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS SHAPING MARKET 38
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40
3 PREMIUM INSIGHTS 41
3.1 CAR T-CELL THERAPY MARKET OVERVIEW 41
3.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC
AND COUNTRY, 2025 42
3.3 CAR T-CELL THERAPY MARKET: GEOGRAPHIC SNAPSHOT 43
4 MARKET OVERVIEW 44
4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Technological advancements in CAR T-cell therapies 45
4.2.1.2 Label expansions and strong efficacy signals in hematologic cancers 45
4.2.1.3 Growing investment in CAR T-cell therapy development 45
4.2.2 RESTRAINTS 46
4.2.2.1 High cost and reimbursement challenges for CAR T-cell therapy 46
4.2.3 OPPORTUNITIES 47
4.2.3.1 Expanding beyond hematologic malignancies into solid tumors and new disease areas 47
4.2.3.2 Focus shift on allogeneic CAR-T and CAR-NK 48
4.2.3.3 Growing collaborations among biopharmaceutical companies, academic institutions, and research organizations 49

4.2.4 CHALLENGES 51
4.2.4.1 Long-term safety surveillance and evolving labeling requirements 51
4.3 UNMET NEEDS & WHITE SPACES 51
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 51
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52
4.6 PIPELINE ANALYSIS 52
5 INDUSTRY TRENDS 55
5.1 PORTER’S FIVE FORCES ANALYSIS 55
5.1.1 THREAT OF NEW ENTRANTS 56
5.1.2 THREAT OF SUBSTITUTES 56
5.1.3 BARGAINING POWER OF BUYERS 56
5.1.4 BARGAINING POWER OF SUPPLIERS 57
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 57
5.2 MACROECONOMIC OUTLOOK 57
5.2.1 INTRODUCTION 57
5.2.2 GDP TRENDS AND FORECASTS 58
5.2.3 TRENDS IN GLOBAL CAR-T-CELL THERAPY MARKET 58
5.3 VALUE CHAIN ANALYSIS 58
5.4 ECOSYSTEM ANALYSIS 60
5.4.1 ROLE IN ECOSYSTEM 61
5.5 PRICING ANALYSIS 62
5.5.1 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS,
BY TYPE, 2025 62
5.5.2 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS,
BY KEY PLAYER, 2025 63
5.5.3 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS,
BY REGION, 2025 64
5.6 KEY CONFERENCES & EVENTS, 2026–2027 64
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 65
5.8 INVESTMENT/FUNDING SCENARIO 66
5.9 IMPACT OF 2025 US TARIFF ON CAR T-CELL THERAPY MARKET 67
5.9.1 KEY TARIFF RATES 67
5.9.2 PRICE IMPACT ANALYSIS 68
5.9.3 IMPACT ON COUNTRY/REGION 68
5.9.3.1 North America 68
5.9.3.1.1 US 68
5.9.3.2 Europe 69
5.9.3.3 Asia Pacific 69
5.9.4 IMPACT ON END-USE INDUSTRIES 70
5.9.4.1 Hospitals 70
5.9.4.2 Specialty oncology centers 70
5.9.4.3 Long-term care facilities 71
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 72
6.1 TECHNOLOGY ANALYSIS 72
6.1.1 KEY TECHNOLOGIES 72
6.1.1.1 Car design and optimization 72
6.1.1.2 Viral vector technology 72
6.1.1.3 Cell culture and expansion techniques 73
6.1.2 COMPLEMENTARY TECHNOLOGIES 73
6.1.2.1 Gene editing technology (CRISPR-CAS9-based genome editing) 73
6.1.3 ADJACENT TECHNOLOGIES 74
6.1.3.1 Monitoring and imaging technologies 74
6.2 TECHNOLOGY/PRODUCT ROADMAP 75
6.3 FUTURE APPLICATIONS 75
6.4 IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET 75
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 77
7.1 REGIONAL REGULATIONS AND COMPLIANCE 77
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
7.1.2 REGULATORY FRAMEWORK 79
7.1.3 INDUSTRY STANDARDS 81
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 81
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 82
7.4 REIMBURSEMENT SCENARIO 83
7.5 COMBINATION THERAPIES 84
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 86
8.1 DECISION-MAKING PROCESS 86
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 86
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
8.2.2 KEY BUYING CRITERIA, BY END USER 87
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 88
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 89
8.5 MARKET PROFITABILITY 89
9 CAR T-CELL THERAPY MARKET, BY PRODUCT 90
9.1 INTRODUCTION 91
9.2 ABECMA 92
9.2.1 FOCUS ON INCREASED RESEARCH ACTIVITIES FOR
INDICATION EXPANSIONS TO DRIVE MARKET 92
9.3 BREYANZI 96
9.3.1 NEED FOR TREATMENT OF MULTIPLE INDICATIONS TO
PROPEL MARKET GROWTH 96
9.4 CARVYKTI 100
9.4.1 GLOBAL REACH AND SIGNIFICANT REVENUE GROWTH TO SUPPORT MARKET 100
9.5 YESCARTA 104
9.5.1 FOCUS ON REGULATORY APPROVALS ACROSS MAJOR REGIONS TO BOOST MARKET GROWTH 104
9.6 TECARTUS 107
9.6.1 EFFORTS TO SECURE REIMBURSEMENT AND IMPROVE MARKET ACCESS FACILITATE PATIENT TO AID MARKET ADOPTION 107
9.7 KYMRIAH 110
9.7.1 APPROVAL FOR PEDIATRIC USE TO AUGMENT MARKET GROWTH 110
9.8 OTHER PRODUCTS 113
10 CAR T-CELL THERAPY MARKET, BY TARGET 117
10.1 INTRODUCTION 118
10.2 CD19 118
10.2.1 RISING INDICATION EXPANSIONS AND NEW APPROVALS TO DRIVE MARKET 118
10.3 BCMA 122
10.3.1 GROWING PIPELINE PRODUCTS TO PROPEL MARKET GROWTH 122
10.4 CD19/20 126
10.4.1 DUAL TARGETING TO OFFER COMPETITIVE ADVANTAGE IN ANTIGEN ESCAPE AND TUMOR HETEROGENEITY ISSUES 126
10.5 CD7 129
10.5.1 ALLOGENEIC CELL SOURCE OF CD7 THERAPIES IN DEVELOPMENT TO SUPPORT GROWTH 129
10.6 OTHER TARGETS 132
11 CAR T-CELL THERAPY MARKET, BY INDICATION 136
11.1 INTRODUCTION 137
11.2 B-CELL LYMPHOMA (BCL) 137
11.2.1 RISING PREVALENCE OF B-CELL LYMPHOMAS TO PROPEL MARKET GROWTH 137
11.3 MULTIPLE MYELOMA 141
11.3.1 GROWING PRODUCT REVENUE AND RISING GLOBAL INCIDENCE OF MYELOMA TO DRIVE MARKET 141
11.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 144
11.4.1 EXPANDING R&D PIPELINE TO AUGMENT MARKET GROWTH 144
11.5 OTHER INDICATIONS 148
12 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC 152
12.1 INTRODUCTION 153
12.2 ADULTS 153
12.2.1 GROWING PREVALENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET 153
12.3 PEDIATRIC 156
12.3.1 HIGH UNMET NEEDS TO LIMIT SEGMENT GROWTH 156
13 CAR T-CELL THERAPY MARKET, BY END USER 160
13.1 INTRODUCTION 161
13.2 HOSPITALS 161
13.2.1 GROWING NEED FOR STANDARD ONCOLOGY TREATMENT
PROTOCOLS TO DRIVE MARKET 161
13.3 SPECIALTY CENTRES 165
13.3.1 NEED FOR OPTIMAL PATIENT CARE AND SPECIALIZED TREATMENT OPTIONS TO SPUR MARKET GROWTH 165
13.4 LONG-TERM CARE FACILITIES 168
13.4.1 INCREASING INCIDENCE OF CHRONIC DISORDERS AMONG GERIATRIC POPULATION TO PROPEL MARKET GROWTH 168
14 CAR T-CELL THERAPY MARKET, BY REGION 172
14.1 INTRODUCTION 173
14.2 NORTH AMERICA 173
14.2.1 US 177
14.2.1.1 US to dominate CAR T-cell therapy market during study period 177
14.2.2 CANADA 179
14.2.2.1 Regulatory approvals and government initiatives for regenerative medicine research to drive market 179
14.3 EUROPE 181
14.3.1 GERMANY 183
14.3.1.1 Key product approvals and focus on clinical research to aid market growth 183
14.3.2 UK 185
14.3.2.1 Technological advancements in automation and presence of robust research infrastructure to spur market growth 185
14.3.3 FRANCE 187
14.3.3.1 Growing focus on cell & gene therapy initiatives to boost market growth 187
14.3.4 ITALY 189
14.3.4.1 Growth in biotech sector to augment market growth 189
14.3.5 SPAIN 191
14.3.5.1 Rising focus on cell therapies and growing focus on stringent regulations to augment market growth 191
14.3.6 REST OF EUROPE 193
14.4 ASIA PACIFIC 196
14.4.1 CHINA 199
14.4.1.1 Rising number of CAR T-cell clinical trials to fuel market growth 199
14.4.2 JAPAN 202
14.4.2.1 Increasing number of product approvals and rising geriatric population to propel market growth 202

14.4.3 INDIA 204
14.4.3.1 Growing focus on product commercialization and rising cancer incidence to boost market demand 204
14.4.4 AUSTRALIA 206
14.4.4.1 Robust infrastructure for clinical trials and well-developed healthcare sector to aid market growth 206
14.4.5 SOUTH KOREA 209
14.4.5.1 Growth in biopharmaceutical industry to facilitate market growth 209
14.4.6 REST OF ASIA PACIFIC 211
14.5 LATIN AMERICA 213
14.5.1 BRAZIL 216
14.5.1.1 Product approvals and high healthcare expenditure to support market growth 216
14.5.2 REST OF LATIN AMERICA 218
14.6 MIDDLE EAST 221
14.6.1 GCC COUNTRIES 223
14.6.2 KINGDOM OF SAUDI ARABIA 226
14.6.2.1 Increased number of product approvals and high healthcare expenditure to boost market growth 226
14.6.3 UAE 228
14.6.3.1 UAE market growth to be driven by localized manufacturing, expanded clinical applications, and strategic collaborations 228
14.6.4 REST OF MIDDLE EAST 230
14.7 AFRICA 232
14.7.1 SIGNIFICANT BURDEN OF HEMATOLOGIC MALIGNANCIES AND INFECTIOUS DISEASES TO PROPEL MARKET GROWTH 232
15 COMPETITIVE LANDSCAPE 235
15.1 INTRODUCTION 235
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN 235
15.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET 235
15.3 REVENUE ANALYSIS, 2023–2025 237
15.4 MARKET SHARE ANALYSIS, 2025 237
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 240
15.5.1 STARS 240
15.5.2 EMERGING LEADERS 240
15.5.3 PERVASIVE PLAYERS 240
15.5.4 PARTICIPANTS 240
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 242
15.5.5.1 Company footprint 242
15.5.5.2 Region footprint 243
15.5.5.3 Product footprint 244
15.5.5.4 Target footprint 245
15.5.5.5 Indication footprint 246
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 246
15.6.1 PROGRESSIVE COMPANIES 246
15.6.2 RESPONSIVE COMPANIES 246
15.6.3 DYNAMIC COMPANIES 246
15.6.4 STARTING BLOCKS 247
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 248
15.6.5.1 Detailed list of key startups/SMEs 248
15.6.5.2 Competitive benchmarking of startups/SMEs 249
15.7 COMPANY VALUATION & FINANCIAL METRICS 250
15.7.1 FINANCIAL METRICS 250
15.7.2 COMPANY VALUATION 250
15.8 BRAND/PRODUCT COMPARISON 251
15.9 COMPETITIVE SCENARIO 252
15.9.1 PRODUCT APPROVALS 252
15.9.2 DEALS 253
15.9.3 EXPANSIONS 253
15.9.4 OTHER DEVELOPMENTS 254
16 COMPANY PROFILES 255
16.1 KEY PLAYERS 255
16.1.1 JOHNSON & JOHNSON 255
16.1.1.1 Business overview 255
16.1.1.2 Products offered 256
16.1.1.3 Recent developments 257
16.1.1.3.1 Product approvals 257
16.1.1.3.2 Deals 257
16.1.1.4 MnM view 258
16.1.1.4.1 Key strengths 258
16.1.1.4.2 Strategic choices 258
16.1.1.4.3 Weaknesses & competitive threats 258
16.1.2 GILEAD SCIENCES, INC. 259
16.1.2.1 Business overview 259
16.1.2.2 Products offered 260
16.1.2.3 Recent developments 261
16.1.2.3.1 Product approvals 261
16.1.2.3.2 Deals 262
16.1.2.3.3 Other developments 262
16.1.2.4 MnM view 263
16.1.2.4.1 Key strengths 263
16.1.2.4.2 Strategic choices 263
16.1.2.4.3 Weaknesses & competitive threats 263
16.1.3 BRISTOL-MYERS SQUIBB COMPANY 264
16.1.3.1 Business overview 264
16.1.3.2 Products offered 266
16.1.3.3 Recent developments 266
16.1.3.3.1 Product approvals 266
16.1.3.3.2 Deals 268
16.1.3.4 MnM view 268
16.1.3.4.1 Key strengths 268
16.1.3.4.2 Strategic choices 268
16.1.3.4.3 Weaknesses & competitive threats 268
16.1.4 NOVARTIS AG 269
16.1.4.1 Business overview 269
16.1.4.2 Products offered 271
16.1.4.3 Recent developments 271
16.1.4.3.1 Product approvals 271
16.1.4.3.2 Other developments 272
16.1.4.4 MnM view 272
16.1.4.4.1 Key strengths 272
16.1.4.4.2 Strategic choices 272
16.1.4.4.3 Weaknesses & competitive threats 272
16.1.5 AUTOLUS THERAPEUTICS 273
16.1.5.1 Business overview 273
16.1.5.2 Products offered 273
16.1.5.3 Recent developments 274
16.1.5.3.1 Product approvals 274
16.1.5.3.2 Deals 274
16.1.5.4 MnM view 274
16.1.5.4.1 Key strengths 274
16.1.5.4.2 Strategic choices 275
16.1.5.4.3 Weaknesses & competitive threats 275
16.1.6 JW (CAYMAN) THERAPEUTICS CO., LTD. 276
16.1.6.1 Business overview 276
16.1.6.2 Products offered 277
16.1.6.3 Recent developments 277
16.1.6.3.1 Product approvals 277
16.1.6.3.2 Deals 278
16.1.7 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT) 279
16.1.7.1 Business overview 279
16.1.7.2 Products offered 279
16.1.7.3 Recent developments 280
16.1.7.3.1 Deals 280
16.1.7.3.2 Other developments 281
16.1.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED 282
16.1.8.1 Business overview 282
16.1.8.2 Products offered 283
16.1.8.3 Recent developments 284
16.1.8.3.1 Product approvals 284
16.1.8.3.2 Deals 285
16.1.8.3.3 Expansions 285
16.1.9 IASO BIOTHERAPEUTICS 286
16.1.9.1 Business overview 286
16.1.9.2 Products offered 286
16.1.9.3 Recent developments 287
16.1.9.3.1 Product approvals 287
16.1.9.3.2 Deals 287
16.1.10 IMMUNEEL THERAPEUTICS 289
16.1.10.1 Business overview 289
16.1.10.2 Products offered 289
16.1.10.3 Recent developments 290
16.1.10.3.1 Product launches 290
16.2 OTHER PLAYERS 290
16.2.1 WUGEN 290
16.2.2 CARTESIAN THERAPEUTICS, INC. 291
16.2.3 ALLOGENE THERAPEUTICS 292
16.2.4 LYELL IMMUNOPHARMA, INC. 293
16.2.5 KYVERNA THERAPEUTICS, INC. 293
16.2.6 CELLICTIS SA 294
16.2.7 BRAINCHILD BIO 294
16.2.8 ATARA BIOTHERAPEUTICS, INC. 295
16.2.9 CARIBOU BIOSCIENCES 295
16.2.10 ARCELLX 296
16.2.11 CRISPR THERAPEUTICS 297
16.2.12 POSEIDA THERAPEUTICS 298
16.2.13 CABALETTA BIO 298
17 RESEARCH METHODOLOGY 299
17.1 RESEARCH DATA 299
17.1.1 SECONDARY DATA 300
17.1.1.1 Objectives of secondary research 300
17.1.2 PRIMARY DATA 301
17.1.2.1 Breakdown of primaries 301
17.1.2.2 Objectives of primary research 302

17.2 MARKET SIZE ESTIMATION 302
17.2.1 BOTTOM-UP APPROACH 303
17.2.2 INSIGHTS FROM PRIMARY EXPERTS 305
17.2.3 SEGMENTAL MARKET SIZE ESTIMATION 306
17.3 GROWTH RATE ASSUMPTIONS 307
17.3.1 CAGR PROJECTIONS 307
17.3.2 IMPACT OF SUPPLY- AND DEMAND-SIDE FACTORS 308
17.4 DATA TRIANGULATION 308
17.5 RESEARCH LIMITATIONS 309
17.6 STUDY ASSUMPTIONS 310
17.7 RISK ANALYSIS 311
18 APPENDIX 312
18.1 DISCUSSION GUIDE 312
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316
18.3 CUSTOMIZATION OPTIONS 318
18.4 RELATED REPORTS 318
18.5 AUTHOR DETAILS 319

LIST OF TABLES

TABLE 1 CAR T-CELL THERAPY MARKET: INCLUSIONS & EXCLUSIONS 33
TABLE 2 KEY PIPELINE PRODUCTS IN PHASE-2 AND PHASE-3 CAR T-CELL
THERAPY MARKET (AS OF 2025) 53
TABLE 3 IMPACT OF PORTER’S FIVE FORCES ON CAR T-CELL THERAPY MARKET 56
TABLE 4 ROLE OF MAJOR COMPANIES IN CAR T-CELL THERAPY MARKET ECOSYSTEM (SUPPLY AND DEMAND SIDES) 61
TABLE 5 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS,
BY TYPE, 2025 (USD) 62
TABLE 6 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY REGION, 2025 64
TABLE 7 KEY CONFERENCES & EVENTS IN CAR T-CELL THERAPY MARKET,
JANUARY 2026–DECEMBER 2027 64
TABLE 8 US-ADJUSTED RECIPROCAL TARIFF RATES 67
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 13 COUNTRY-WISE REGULATORY SCENARIO FOR CAR T-CELL
THERAPY PRODUCT MANUFACTURERS 80
TABLE 14 CAR T-CELL THERAPY MARKET: REIMBURSEMENT STATUS AND
FUNDING CHANNEL, BY COUNTRY/REGION (AS OF 2026) 83
TABLE 15 CAR T-CELL THERAPY MARKET: HCPCS CODES OF COMMERCIALIZED THERAPIES 84
TABLE 16 COMBINATION THERAPY TRIALS IN CAR T-CELL THERAPY MARKET 85
TABLE 17 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 86
TABLE 18 KEY BUYING CRITERIA, BY END USER 87
TABLE 19 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 91
TABLE 20 CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (NUMBER OF THERAPIES) 91
TABLE 21 CAR T-CELL THERAPY MARKET FOR ABECMA, BY REGION,
2024–2031 (USD MILLION) 93
TABLE 22 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ABECMA,
BY COUNTRY, 2024–2031 (USD MILLION) 93
TABLE 23 EUROPE: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY,
2024–2031 (USD MILLION) 94
TABLE 24 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY,
2024–2031 (USD MILLION) 94
TABLE 25 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION) 95
TABLE 26 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY,
2024–2031 (USD MILLION) 95
TABLE 27 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ABECMA,
BY COUNTRY, 2024–2031 (USD MILLION) 95
TABLE 28 CAR T-CELL THERAPY MARKET FOR BREYANZI, BY REGION,
2024–2031 (USD MILLION) 97
TABLE 29 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION) 97
TABLE 30 EUROPE: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY,
2024–2031 (USD MILLION) 98
TABLE 31 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY,
2024–2031 (USD MILLION) 98
TABLE 32 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION) 99
TABLE 33 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY,
2024–2031 (USD MILLION) 99
TABLE 34 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION) 99
TABLE 35 CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY REGION,
2024–2031 (USD MILLION) 101
TABLE 36 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION) 101
TABLE 37 EUROPE: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY,
2024–2031 (USD MILLION) 102
TABLE 38 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY,
2024–2031 (USD MILLION) 102
TABLE 39 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 40 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY,
2024–2031 (USD MILLION) 103
TABLE 41 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR CARVYKTI,
BY COUNTRY, 2024–2031 (USD MILLION) 103
TABLE 42 CAR T-CELL THERAPY MARKET FOR YESCARTA, BY REGION,
2024–2031 (USD MILLION) 104
TABLE 43 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION) 105
TABLE 44 EUROPE: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY,
2024–2031 (USD MILLION) 105
TABLE 45 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY,
2024–2031 (USD MILLION) 106
TABLE 46 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 47 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION) 106
TABLE 48 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION) 107
TABLE 49 CAR T-CELL THERAPY MARKET FOR TECARTUS, BY REGION,
2024–2031 (USD MILLION) 107
TABLE 50 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 51 EUROPE: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY,
2024–2031 (USD MILLION) 108
TABLE 52 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY,
2024–2031 (USD MILLION) 109
TABLE 53 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 54 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION) 109
TABLE 55 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 56 CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY REGION,
2024–2031 (USD MILLION) 111
TABLE 57 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 58 EUROPE: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY,
2024–2031 (USD MILLION) 111
TABLE 59 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY,
2024–2031 (USD MILLION) 112
TABLE 60 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION) 112
TABLE 61 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY,
2024–2031 (USD MILLION) 112
TABLE 62 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION) 113
TABLE 63 CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY REGION,
2024–2031 (USD MILLION) 114
TABLE 64 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 65 EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 114
TABLE 66 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 67 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 68 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 69 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 70 CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 118
TABLE 71 COMMERCIALLY AVAILABLE CD19 ANTIGEN TARGETING CAR T-CELL THERAPIES 119
TABLE 72 CD19-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 119
TABLE 73 NORTH AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 74 EUROPE: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 120
TABLE 75 ASIA PACIFIC: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 76 LATIN AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 77 MIDDLE EAST: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 78 GCC COUNTRIES: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 79 COMMERCIALLY AVAILABLE BCMA ANTIGEN TARGETING CAR T-CELL THERAPIES 123
TABLE 80 BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 81 NORTH AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 82 EUROPE: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 83 ASIA PACIFIC: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 84 LATIN AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 85 MIDDLE EAST: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 86 GCC COUNTRIES: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 87 CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 88 NORTH AMERICA: CD19/20-TARGETING CAR T-CELL THERAPY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 89 EUROPE: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 90 ASIA PACIFIC: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 91 LATIN AMERICA: CD19/20-TARGETING CAR T-CELL THERAPY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 92 MIDDLE EAST: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 93 GCC COUNTRIES: CD19/20-TARGETING CAR T-CELL THERAPY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 94 CD7-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2024–2031 (USD MILLION) 129
TABLE 95 NORTH AMERICA: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 96 EUROPE: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 130
TABLE 97 ASIA PACIFIC: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 98 LATIN AMERICA: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 99 MIDDLE EAST: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 100 GCC COUNTRIES: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 101 OTHER CAR T-CELL THERAPY TARGETS MARKET, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 102 NORTH AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 103 EUROPE: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 104 ASIA PACIFIC: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 105 LATIN AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 106 MIDDLE EAST: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 107 GCC COUNTRIES: OTHER CAR T-CELL THERAPY TARGETS MARKETA, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 108 CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 137
TABLE 109 CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY REGION,
2024–2031 (USD MILLION) 138
TABLE 110 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 111 EUROPE: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL),
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 112 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL),
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 113 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL),
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 114 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL),
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 115 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL),
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 116 CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY REGION,
2024–2031(USD MILLION) 141
TABLE 117 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA,
BY COUNTRY, 2024–2031(USD MILLION) 142
TABLE 118 EUROPE: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031(USD MILLION) 142
TABLE 119 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA,
BY COUNTRY, 2024–2031(USD MILLION) 143
TABLE 120 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 121 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 122 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELLOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 123 CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL),
BY REGION, 2024–2031(USD MILLION) 145
TABLE 124 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION) 145
TABLE 125 EUROPE: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION) 146
TABLE 126 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION) 146
TABLE 127 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 128 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 129 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 130 CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 131 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 132 EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 133 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 134 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 135 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 136 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 137 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION) 153
TABLE 138 CAR T-CELL THERAPY MARKET FOR ADULTS, BY REGION,
2024–2031 (USD MILLION) 154
TABLE 139 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 140 EUROPE: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 141 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 142 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 143 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 144 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 145 CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY REGION,
2024–2031 (USD MILLION) 157
TABLE 146 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRIC,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 147 EUROPE: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 148 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY,
2024–2031 (USD MILLION) 158
TABLE 149 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 150 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031(USD MILLION) 158
TABLE 151 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR PEDIATRIC,
BY COUNTRY, 2024–2031(USD MILLION) 159
TABLE 152 CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 161
TABLE 153 CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 154 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 155 EUROPE: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 156 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031(USD MILLION) 163
TABLE 157 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 158 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 159 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031(USD MILLION) 164
TABLE 160 CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY REGION,
2024–2031 (USD MILLION) 165
TABLE 161 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 162 EUROPE: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 163 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 164 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 165 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES,
BY COUNTRY, 2024–2031(USD MILLION) 167
TABLE 166 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES,
BY COUNTRY, 2024–2031(USD MILLION) 168
TABLE 167 CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2031(USD MILLION) 169
TABLE 168 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION) 169
TABLE 169 EUROPE: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2024–2031(USD MILLION) 169
TABLE 170 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2024–2031(USD MILLION) 170
TABLE 171 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION) 170
TABLE 172 MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION) 170
TABLE 173 GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION) 171
TABLE 174 CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 175 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 176 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 175
TABLE 177 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 175
TABLE 178 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 176
TABLE 179 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 176
TABLE 180 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 176
TABLE 181 US: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 177
TABLE 182 US: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 178
TABLE 183 US: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 178
TABLE 184 US: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 178
TABLE 185 US: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 179
TABLE 186 CANADA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 179
TABLE 187 CANADA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 180
TABLE 188 CANADA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 180
TABLE 189 CANADA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 180
TABLE 190 CANADA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 181
TABLE 191 EUROPE: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 192 EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 182
TABLE 193 EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 182
TABLE 194 EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 182
TABLE 195 EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 183
TABLE 196 EUROPE: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 183
TABLE 197 GERMANY: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 184
TABLE 198 GERMANY: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 184
TABLE 199 GERMANY: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 184
TABLE 200 GERMANY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 185
TABLE 201 GERMANY: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 185
TABLE 202 UK: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 186
TABLE 203 UK: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 186
TABLE 204 UK: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 186
TABLE 205 UK: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 187
TABLE 206 UK: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 187
TABLE 207 FRANCE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 188
TABLE 208 FRANCE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 188
TABLE 209 FRANCE: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 188
TABLE 210 FRANCE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 189
TABLE 211 FRANCE: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 189
TABLE 212 ITALY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 190
TABLE 213 ITALY: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 190
TABLE 214 ITALY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 190
TABLE 215 ITALY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 191
TABLE 216 ITALY: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 191
TABLE 217 SPAIN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 192
TABLE 218 SPAIN: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 192
TABLE 219 SPAIN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 192
TABLE 220 SPAIN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 193
TABLE 221 SPAIN: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 193
TABLE 222 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 194
TABLE 223 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 194
TABLE 224 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 195
TABLE 225 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 195
TABLE 226 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 195
TABLE 227 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 228 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 197
TABLE 229 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 198
TABLE 230 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 198
TABLE 231 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 198
TABLE 232 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 199
TABLE 233 CHINA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200
TABLE 234 CHINA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 200
TABLE 235 CHINA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 201
TABLE 236 CHINA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 201
TABLE 237 CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 201
TABLE 238 JAPAN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 202
TABLE 239 JAPAN: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 203
TABLE 240 JAPAN: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 203
TABLE 241 JAPAN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 203
TABLE 242 JAPAN: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 204
TABLE 243 INDIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 204
TABLE 244 INDIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 205
TABLE 245 INDIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 205
TABLE 246 INDIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 205
TABLE 247 INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 206
TABLE 248 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 207
TABLE 249 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 207
TABLE 250 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 208
TABLE 251 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 208
TABLE 252 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 208
TABLE 253 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 209
TABLE 254 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 209
TABLE 255 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 210
TABLE 256 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 210
TABLE 257 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 210
TABLE 258 REST OF ASIA PACIFC: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 211
TABLE 259 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 212
TABLE 260 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 212
TABLE 261 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 213
TABLE 262 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 213
TABLE 263 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 264 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 214
TABLE 265 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 214
TABLE 266 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 215
TABLE 267 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 215
TABLE 268 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 215
TABLE 269 BRAZIL: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 216
TABLE 270 BRAZIL: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 217
TABLE 271 BRAZIL: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 217
TABLE 272 BRAZIL: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 217
TABLE 273 BRAZIL: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 218
TABLE 274 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 219
TABLE 275 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 219
TABLE 276 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 220
TABLE 277 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION) 220
TABLE 278 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 279 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 280 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 222
TABLE 281 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 222
TABLE 282 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 222
TABLE 283 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 223
TABLE 284 MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 223
TABLE 285 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 286 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 224
TABLE 287 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 224
TABLE 288 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 225
TABLE 289 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 225
TABLE 290 GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 225
TABLE 291 KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 226
TABLE 292 KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 227
TABLE 293 KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 227
TABLE 294 KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION) 227
TABLE 295 KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 228
TABLE 296 UAE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 228
TABLE 297 UAE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 229
TABLE 298 UAE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION) 229
TABLE 299 UAE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 229
TABLE 300 UAE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 230
TABLE 301 REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 230
TABLE 302 REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY TARGET,
2024–2031 (USD MILLION) 231
TABLE 303 REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 231
TABLE 304 REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 231
TABLE 305 REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY END USER,
2024–2031 (USD MILLION) 232
TABLE 306 AFRICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 233
TABLE 307 AFRICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION) 233
TABLE 308 AFRICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2024–2031 (USD MILLION) 233
TABLE 309 AFRICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2024–2031 (USD MILLION) 234
TABLE 310 AFRICA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 234
TABLE 311 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
CAR T-CELL THERAPY MARKET 235
TABLE 312 CAR T-CELL THERAPY MARKET: DEGREE OF COMPETITION 238
TABLE 313 CAR T-CELL THERAPY MARKET: REGION FOOTPRINT 243
TABLE 314 CAR T-CELL THERAPY MARKET: PRODUCT FOOTPRINT 244
TABLE 315 CAR T-CELL THERAPY MARKET: TARGET FOOTPRINT 245
TABLE 316 CAR T-CELL THERAPY MARKET: INDICATION FOOTPRINT 246
TABLE 317 CAR T-CELL THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 248
TABLE 318 CAR T-CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY DEMOGRAPHY AND REGION, 2025 249
TABLE 319 CAR T-CELL THERAPY MARKET: PRODUCT APPROVALS,
JANUARY 2022–JANUARY 2026 252
TABLE 320 CAR T-CELL THERAPY MARKET: DEALS, JANUARY 2022–JANUARY 2026 253
TABLE 321 CAR T-CELL THERAPY MARKET: EXPANSIONS, JANUARY 2022–JANUARY 2026 253
TABLE 322 CAR T-CELL THERAPY MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–JANUARY 2026 254
TABLE 323 JOHNSON & JOHNSON: COMPANY OVERVIEW 255
TABLE 324 JOHNSON & JOHNSON: PRODUCTS OFFERED 256
TABLE 325 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026 257
TABLE 326 JOHNSON & JOHNSON: DEALS, JANUARY 2022−JANUARY 2026 257
TABLE 327 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 259
TABLE 328 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 260
TABLE 329 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2022–JANUARY 2026 261
TABLE 330 GILEAD SCIENCES, INC.: DEALS, JANUARY 2022–JANUARY 2026 262
TABLE 331 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2026 262
TABLE 332 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 264
TABLE 333 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 266
TABLE 334 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS,
JANUARY 2022–JANUARY 2026 266
TABLE 335 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2022–JANUARY 2026 268
TABLE 336 NOVARTIS AG: COMPANY OVERVIEW 269
TABLE 337 NOVARTIS AG: PRODUCTS OFFERED 271
TABLE 338 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026 271
TABLE 339 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2022−JANUARY 2026 272
TABLE 340 AUTOLUS THERAPEUTICS: COMPANY OVERVIEW 273
TABLE 341 AUTOLUS THERAPEUTICS: PRODUCTS OFFERED 273
TABLE 342 AUTOLUS THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026 274
TABLE 343 AUTOLUS THERAPEUTICS: DEALS, JANUARY 2022−JANUARY 2026 274
TABLE 344 JW (CAYMAN) THERAPEUTICS CO., LTD.: COMPANY OVERVIEW 276
TABLE 345 JW (CAYMAN) THERAPEUTICS CO., LTD.: PRODUCTS OFFERED 277
TABLE 346 JW (CAYMAN) THERAPEUTICS CO., LTD.: PRODUCT APPROVALS,
JANUARY 2022−JANUARY 2026 277
TABLE 347 JW (CAYMAN) THERAPEUTICS CO., LTD.: DEALS, JANUARY 2022−JANUARY 2026 278
TABLE 348 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT):
COMPANY OVERVIEW 279
TABLE 349 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT):
PRODUCTS OFFERED 279
TABLE 350 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT):
DEALS, JANUARY 2022−JANUARY 2026 280
TABLE 351 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT):
OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2026 281
TABLE 352 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW 282
TABLE 353 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED 283
TABLE 354 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS,
JANUARY 2022−JANUARY 2026 284
TABLE 355 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS,
JANUARY 2022−JANUARY 2026 285
TABLE 356 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS, JANUARY 2022−JANUARY 2026 285
TABLE 357 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW 286
TABLE 358 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED 286
TABLE 359 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026 287
TABLE 360 IASO BIOTHERAPEUTICS: DEALS, JANUARY 2022−JANUARY 2026 287
TABLE 361 IMMUNEEL THERAPEUTICS: COMPANY OVERVIEW 289
TABLE 362 IMMUNEEL THERAPEUTICS: PRODUCTS OFFERED 289
TABLE 363 IMMUNEEL THERAPEUTICS: PRODUCT LAUNCHES, JANUARY 2022−JANUARY 2026 290
TABLE 364 WUGEN: COMPANY OVERVIEW 290
TABLE 365 CARTESIAN THERAPEUTICS, INC.: COMPANY OVERVIEW 291
TABLE 366 ALLOGENE THERAPEUTICS: COMPANY OVERVIEW 292
TABLE 367 LYELL IMMUNOPHARMA, INC.: COMPANY OVERVIEW 293
TABLE 368 KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW 293
TABLE 369 CELLICTIS SA: COMPANY OVERVIEW 294
TABLE 370 BRAINCHILD BIO: COMPANY OVERVIEW 294
TABLE 371 ATARA BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW 295
TABLE 372 CARIBOU BIOSCIENCES: COMPANY OVERVIEW 295
TABLE 373 ARCELLX: COMPANY OVERVIEW 296
TABLE 374 CRISPR THERAPEUTICS: COMPANY OVERVIEW 297
TABLE 375 POSEIDA THERAPEUTICS: COMPANY OVERVIEW 298
TABLE 376 CABALETTA BIO: COMPANY OVERVIEW 298

TABLE 377 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON CAR T-CELL THERAPY MARKET 308
TABLE 378 CAR T-CELL THERAPY MARKET: RISK ANALYSIS 311

LIST OF FIGURES

FIGURE 1 CAR T-CELL THERAPY MARKET SEGMENTATION & REGIONAL SCOPE 32
FIGURE 2 CAR T-CELL THERAPY MARKET: YEARS CONSIDERED 34
FIGURE 3 CAR T-CELL THERAPY MARKET SCENARIO 36
FIGURE 4 GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2024–2031 (USD MILLION) 37
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CAR T-CELL
THERAPY MARKET, 2023–2025 37
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF CAR T-CELL THERAPY MARKET 38
FIGURE 7 HIGH-GROWTH SEGMENTS IN CAR T-CELL THERAPY MARKET, BY PRODUCT, TARGET, END USER, AND REGION, 2026–2031 39
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CAR T-CELL THERAPY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 40
FIGURE 9 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPIES TO DRIVE GROWTH 41
FIGURE 10 US AND ADULTS DOMINATED NORTH AMERICAN CAR T-CELL
THERAPY MARKET IN 2025 42
FIGURE 11 INDIA TO REGISTER FASTEST GROWTH RATE DURING FORECAST PERIOD 43
FIGURE 12 CAR T-CELL THERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 44
FIGURE 13 GLOBAL CAR T-CELL THERAPY TRIALS DISTRIBUTION, BY TARGET
(ACROSS ALL PHASES OF DEVELOPMENT), 2025 54
FIGURE 14 GLOBAL CAR T-CELL THERAPY TRIALS DISTRIBUTION OF TARGET
BY DEVELOPMENT PHASE, 2025 54
FIGURE 15 CAR T-CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 55
FIGURE 16 CAR T-CELL THERAPY MARKET: VALUE CHAIN ANALYSIS 59
FIGURE 17 CAR T-CELL THERAPY MARKET: ECOSYSTEM ANALYSIS 60
FIGURE 18 AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS,
BY KEY PLAYER, 2025 (USD) 63
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
IN CAR T-CELL THERAPY MARKET 65
FIGURE 20 FUNDING AND NUMBER OF DEALS IN CAR T-CELL
THERAPY MARKET (USD MILLION) 66
FIGURE 21 IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET 76
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 86
FIGURE 23 KEY BUYING CRITERIA FOR MAJOR END USERS 87
FIGURE 24 NORTH AMERICA: CAR T-CELL THERAPY MARKET SNAPSHOT 174
FIGURE 25 ASIA PACIFIC: CAR T-CELL THERAPY MARKET SNAPSHOT 196
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET,
2023–2025 (USD MILLION) 237
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN
CAR T-CELL THERAPY MARKET (2025) 238
FIGURE 28 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 241
FIGURE 29 CAR T-CELL MARKET: COMPANY FOOTPRINT 242
FIGURE 30 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 247
FIGURE 31 EV/EBITDA OF KEY VENDORS 250
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 250
FIGURE 33 CAR T-CELL THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 251
FIGURE 34 JOHNSON & JOHNSON: COMPANY SNAPSHOT 256
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT 260
FIGURE 36 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT 265
FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT 270
FIGURE 38 JW (CAYMAN) THERAPEUTICS CO., LTD.: COMPANY SNAPSHOT 276
FIGURE 39 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY SNAPSHOT 283
FIGURE 40 CAR T-CELL THERAPY MARKET: RESEARCH DESIGN 299
FIGURE 41 CAR T-CELL THERAPY MARKET: BREAKDOWN OF
DEMAND– AND SUPPLY-SIDE PRIMARIES 301
FIGURE 42 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 302
FIGURE 43 CAR T-CELL THERAPY MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2025 303
FIGURE 44 ILLUSTRATIVE EXAMPLE OF GILEAD SCIENCES, INC.:
REVENUE SHARE ANALYSIS (2025) 304
FIGURE 45 CAR T-CELL THERAPY MARKET VALIDATION FROM PRIMARY SOURCES 305
FIGURE 46 CAR T-CELL THERAPY MARKET SIZE ESTIMATION METHODOLOGY:
TOP-DOWN APPROACH 306
FIGURE 47 CAR T-CELL THERAPY MARKET: CAGR PROJECTIONS, 2026–2031 307
FIGURE 48 CAR T-CELL THERAPY MARKET: DATA TRIANGULATION METHODOLOGY 309

---

---